ORCHID PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,003 INR | -0.33% |
|
-2.36% | +40.73% |
| 05-24 | Transcript : Orchid Pharma Limited, Q4 2024 Earnings Call, May 24, 2024 | |
| 05-23 | Orchid Pharma Limited Appoints Shubha Singh as Additional Director | CI |
Valuation
| Fiscal Period: March | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 50,856 | - | - |
| Enterprise Value (EV) 1 | 51,673 | 49,208 | 48,809 |
| P/E ratio | 72.1 x | 34 x | 24.3 x |
| Yield | - | - | - |
| Capitalization / Revenue | 6.47 x | 4.95 x | 3.43 x |
| EV / Revenue | 6.31 x | 4.78 x | 3.29 x |
| EV / EBITDA | 46.7 x | 28.7 x | 19.5 x |
| EV / FCF | 84.5 x | -71.9 x | -26 x |
| FCF Yield | 1.18% | -1.39% | -3.85% |
| Price to Book | 4.53 x | 3.86 x | 3.6 x |
| Nbr of stocks (in thousands) | 50,719 | - | - |
| Reference price 2 | 1,003 | 1,003 | 1,003 |
| Announcement Date | 23/05/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | 8,194 | 10,284 | 14,842 |
| EBITDA 1 | - | 1,107 | 1,715 | 2,499 |
| EBIT 1 | - | 774.4 | 1,298 | 1,950 |
| Operating Margin | - | 9.45% | 12.63% | 13.14% |
| Earnings before Tax (EBT) 1 | - | 919.5 | 1,491 | 2,235 |
| Net income 1 | 463.2 | 921.7 | 1,486 | 2,172 |
| Net margin | - | 11.25% | 14.45% | 14.63% |
| EPS 2 | - | 14.49 | 29.50 | 41.23 |
| Free Cash Flow 1 | - | 611.8 | -684.5 | -1,880 |
| FCF margin | - | 7.47% | -6.66% | -12.67% |
| FCF Conversion (EBITDA) | - | 55.28% | - | - |
| FCF Conversion (Net income) | - | 66.38% | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 10/05/23 | 23/05/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2024 Q3 | 2024 Q4 |
|---|---|---|
| Net sales 1 | 2,098 | 2,524 |
| EBITDA 1 | 265.5 | 404 |
| EBIT | - | - |
| Operating Margin | - | - |
| Earnings before Tax (EBT) | - | - |
| Net income 1 | 201 | - |
| Net margin | 9.58% | - |
| EPS 2 | 4.000 | - |
| Dividend per Share | - | - |
| Announcement Date | - | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | - | 1,321 | 1,648 | 2,047 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | 612 | -685 | -1,881 |
| ROE (net income / shareholders' equity) | - | 9.92% | 11.7% | 14.8% |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share 2 | - | 231.0 | 260.0 | 279.0 |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 648 | 2,723 | 4,378 |
| Capex / Sales | - | 7.91% | 26.48% | 29.5% |
| Announcement Date | 10/05/23 | 23/05/24 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,003
INR
Average target price
1,252
INR
Spread / Average Target
+24.90%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +40.73% | 609M | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- ORCHPHARMA Stock
- Financials Orchid Pharma Limited
